← Search & browse all drugs
GENITO URINARY SYSTEM AND SEX HORMONES › SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM › HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE › Progestogens and estrogens, fixed combinations
norgestrel and ethinylestradiol
G03AA06
Forms & Strengths
- Tablets: norgestrel 0.5mg and ethinylestradiol 0.05mg
- Tablets: norgestrel 0.75mg and ethinylestradiol 0.02mg
- Tablets: norgestrel 0.5mg and ethinylestradiol 0.03mg
Adult Dosing
- 1 tablet daily for 21 days, followed by 7 days of placebo or inactive tablets
- Extended or continuous regimens may vary, consult product labeling
Pediatric Dosing
- Not recommended before menarche
- Dosing same as adults for postmenarchal females
Indications
- Contraception
- Treatment of heavy menstrual bleeding
- Treatment of dysmenorrhea
- Treatment of acne
Mechanism of Action
- Inhibition of ovulation by suppression of gonadotropin release
- Thickening of cervical mucus to impede sperm penetration
- Alteration of endometrium to prevent implantation
Contraindications
- Pregnancy
- Breast cancer or other estrogen-dependent neoplasia
- Active liver disease
- Undiagnosed vaginal bleeding
- History of thromboembolic disorders
Adverse Reactions
- Nausea and vomiting
- Breast tenderness
- Headache
- Mood changes
- Weight gain
- Hypertension
- Cholestasis
Drug Interactions
- Increased risk of thrombosis with concomitant use of smoking, age >35 years, or other thrombogenic factors
- Decreased efficacy with concomitant use of rifampicin, phenytoin, or other hepatic enzyme inducers
- Increased risk of adverse effects with concomitant use of other estrogen-containing products
Curated Content: Needs Vetting Before Put to Clinical Use